Table 3.
Variance of continuous CTC-counts according to therapy response after four (q4) or ten cycles (q10) of docetaxel
| Response | CTC-Detection | Radiographic evaluation | Clinical criteria | ||||||
|---|---|---|---|---|---|---|---|---|---|
| q0a | q1a | q4 | q10 | q0a | q1a | q4 | q10 | ||
| non-PD | Median, Range | 5 | 1 | 0 | 0 | 4.5 | 1 | 0 | 0 |
| 0-225 | 0-85 | 0-115 | 0-73 | 0-97 | 0-38 | 0-29 | 0-71 | ||
| Patients, n= | 25 | 25 | 25 | 17 | 24 | 24 | 24 | 14 | |
| PD | Median, Range | 24 | 9.5 | 32 | 23 | 22 | 11 | 34 | 17 |
| 4-97 | 1-58 | 3-358 | 0-36 | 4-225 | 1-85 | 3-358 | 0-73 | ||
| Patients, n= | 8 | 8 | 8 | 6 | 9 | 9 | 9 | 9 | |
| Significance, p= | 0.04 | 0.01 | <0.001 | 0.03 | 0.03 | 0.004 | <0.001 | 0.03 | |
PD, progressive disease according to therapy response assessment at q4 or q10; q, cycle of docetaxel
aCTC-variance was assessed as a function of objective response at q4